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Background
International AIDS Vaccine Initiative and its global part-
ners have or are conducting 22 preventive AIDS vaccine
trials in 940 participants in 11 countries. The initiation of
clinical trials in India prompted to examine referrals, care
and treatment (CT) national guidelines to be offered to
vaccine trial or HIV-infected volunteers.
Methods
National consultations and discussions were held by IAVI
in India to define policy for CT of trial participants within
national guidelines.
Results
CT guidelines formulated and implemented in clinical tri-
als include the following provisions: for volunteer with
adverse events or disabilities due to vaccination, provision
of comprehensive care, diagnosis and treatment without
charge; for volunteer becoming HIV-infected during the
trial, IAVI ensures access to free anti-retroviral therapy (as
per national guidelines) for 5 years after treatment initia-
tion, unless free of charge from other sources. Volunteers
HIV-infected at screening are referred to reliable HIV treat-
ment centers. As personal medical insurance is uncom-
mon, volunteers are provided with medical insurance for
vaccine-unrelated medical events for duration of trial
period. The trial centers provide free of cost consultations,
diagnostic tests, contraceptives and medicines for com-
mon ailments whose annual cost is estimated to $1960.
Cost for insurance is $60/volunteer/year. IAVI maintains
global insurance policy which provides uniform liability
coverage for volunteers injured through participation in
global clinical trials.
Conclusion
IAVI care and treatment policy has become the ''Reference
Standard'' for the Ministry of Health. It ensures volunteers
in IAVI-sponsored research treated according to highest
ethical standards.
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